Lataa...
The End Point Is Just the Beginning
Clinical trials to support registration of new drugs are arduous, lengthy, and expensive. Diabetes treatment trials intended to seek indications for glycemic control are facilitated by the regulatory acceptance of glycosylated hemoglobin (A1C) as a validated intermediate efficacy end point. However,...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Diabetes Technology Society
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3208893/ https://ncbi.nlm.nih.gov/pubmed/22027330 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|